Cancer Targeted Therapy

Anti-Mouse IL-12 p75 Antibody (R2-9A5) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse IL-12 p75. Anti-Mouse IL-12 p75 Antibody (R2-9A5) can neutralize IL-12. Anti-Mouse IL-12 p75 Antibody (R2-9A5) can be used for the researches of infection and cancer, such as E. coli infection and MCA205 sarcoma.

CRBN ligand-409 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-409 can be linked to a target protein ligand via a linker to form a PROTAC.

PI-828 (Standard) is the analytical standard of PI-828 (HY-108606). This product is intended for research and analytical applications. PI-828 is a dual PI3K and casein K_inase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid K_inase assay, respectively.

Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).

Monomethyl auristatin E intermediate-13 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs).

Protein kinase inhibitor 13 (Compound I-90) is the inhibitor for protein kinase that exhibits inhibitory effects on kinases such as PIM-1, CDK-2, GSK-3 and SRC.

Ibrutinib (Racemate) (Standard) is the analytical standard of Ibrutinib (Racemate). This product is intended for research and analytical applications. Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.

CRBN ligand-286 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-286 can be linked to a target protein ligand via a linker to form a PROTAC.

HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and ERBB2 with IC₅₀s of 34 nM and 33 nM, respectively. HKI-357 dimaleate suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.

Pulchinenoside E2 is a triterpenoid saponin. Pulchinenoside E2 inhibits the phosphorylation of STAT3 and JAK2, blocks the nuclear translocation and transcriptional activity of STAT3, and suppresses STAT3-dependent mitochondrial oxidative phosphorylation. Pulchinenoside E2 inhibits invasion, migration and autophagy of triple-negative breast cancer cells. Pulchinenoside E2 can be used in research related to triple-negative breast cancer.

HS-PEG24-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

CRBN ligand-567 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-567 can be linked to a target protein ligand via a linker to form a PROTAC.

Tozasertib (Standard) is the analytical standard of Tozasertib (HY-10161). This product is intended for research and analytical applications. Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with Kis of 0.6, 18, 4.6 nM, respectively.

Fmoc-NH-CH2-PEG3-C2-NH2 (hydrochloride) is a PROTAC linker that can be used in the synthesis of PROTACs.

CRBN ligand-220 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-220 can be linked to a target protein ligand via a linker to form a PROTAC.

BMX-IN-4 is a covalent BMX kinase inhibitor with an IC₅₀ of 1.78 nM and a K_i of 0.158 μM. BMX-IN-4 forms a covalent bond with BMX kinase. BMX-IN-4 is applicable to the research of hepatocellular carcinoma.

TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC₅₀ of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung.

VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent VEGFR-2 inhibitor with an IC₅₀ of 0.037 µM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI₅₀=1.6 µM). VEGFR-2-IN-12 has antitumor activity.

Exatecan Intermediate 1-d₂ is the deuterium labeled Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor with anticancer effects.

Metformin-¹³C₂ (1,1-Dimethylbiguanide-¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.